INTRODUCTION
The deposition of calcium pvrophosphate dihvdrate (CPPD) 1 microcrvstals in articular structures and joint fluid has been called pseudogout (PG) by analogy with sodium urate crystal deposition disease (classic lAbbreviationis used in this paper: CPPD, calcium pyrophosphate dihydrate; G, gout; ["P] PPi, radioactive inorganic pyrophosphate; ['P] Pi, radioactive inorganic orthophosphate; Pi, inorganic orthophosphate; PG, pseudogout; PPi, plasma inorganic pyrophosphate; RA, rheumatoid arthritis; SA, specific activity. gout) (1, 2) . This condition was originally called "articular chondrocalcinosis" by Zitnan and Sitaj, who used the characteristic radiologic appearance as the definitive diagnostic feature (3) . The mechanism leading to formation of this peculiar mineral phase in articular tissues is unknown, but several groups of investigators recently have measured synovial fluid and plasma inorganic pyrophosphate (PPi). Russell et al. first reported that joint fluid PPi in PG averaged eight times the mean levels of plasma or of control joint fluids (4) . The mean and range of PPi in these control fluids and in control and PG plasma were essentially that of normal plasma. All values in PG joint fluid exceeded the highest control value. McCarty, Solomon, Warnock, and Paloyan extended these observations in reporting that the mean joint fluid PPi levels in PG were about five times that of control fluids, but overlap of values between PG and controls were found (5) . All of the above data were obtained using radioisotopic dilution and anion exchange column chromatographic separation of PPi.
Newer analytical methods have been applied to further study of joint fluid PPi levels. Altman, Muniz, Pita, and Howell (6) , using an adaptation of the uridine diphosphoglucose pyrophosphorylase method of Johnson, Shanoff, Bass, Boezi, and Hansen (7) , found elevated PPi levels in osteoarthritis (OA) and gouty synovial fluids and even higher levels in fluids from patients with PG, with respect to fluids from patients with inflammatory types of arthritis and normal or patient plasma. These newer findings have been corroborated by those of Silcox and McCarty using isotopic dilution and yeast inorganic pyrophosphatase (8, 9) . They found comparable PPi elevations in PG and OA synovial fluids and elevated levels in some patients with gout (G) and rheumatoid arthritis (RA), as compared to PPi values in normal or patient plasma. PPi levels were found to be significantly higher in chronically symptomatic PG joints than in actively inflamed joints, and in OA the PPi levels were correlated with the degree of joint degeneration as determined by X-ray examination.
These findings together suggest that elevated PPi levels may occur in joints afflicted with different types of arthritis and that this elevation, if related to the formation of CPPD crystals, may account for their occurrence in some patients with RA (10, 11), G (2, 10, 12) or OA (1, 2, 13 The following experiment was performed to determine whether exchange occurred rapidly enough to influence the apparent clearance rate of intrasynovially injected [32P]PPi: the CPPD crystals in 20 ml of synovial fluid obtained from a patient with definite PG were pelleted by centrifugation at 38°C (20,000 g for 30 min). This procedure will pellet more than 99% of synthetic [4"Ca]CPPD microcrystals (9) . The pH of the fluid had been adjusted to 7.4 with 1 N HCl after prolonged stirring at 38°C. A few crystals of thymol were added for bacteriostasis. 15 ml of crystal-free supernate was transferred to a 50-ml Erlenmeyer flask containing a 10-mm magnetic stirring bar, and 20 mg of synthetic CPPD crystals were added. The remaining fluid, containing all the natural CPPD crystals, was transferred to a second flask. Both flasks were covered with parafilm, placed in an incubator at 380C, and stirred at a constant rate for 20 min. 10 ul of stock ["2P]PPi containing 0.025 ,umol of PPi was then added to each flask. 3-ml samples were removed from each flask at varying times up to 19 h later, and after the addition of 16 U of hyaluronidase (in 5 ,Iu), incubated for 15 min at 380C. This enzyme was used here and later to reduce the viscosity of joint fluid, thereby increasing the efficiency of centrifugation. The crystals in each sample were then separated at 38°C by centrifugation at 20,000 g for 30 min. All procedures after separation were performed at 40C or in crushed ice. 2 ml of supernate was diluted to 5 ml and assayed for PPi by isotopic dilution (8) ; the percentage of nuclide that had hydrolyzed to [32P]Pi was determined by isobutanol extraction as described by Hall (18) and modified by Russell, Bisaz, Donath, Morgan, and Fleisch (19) . The pellet was resuspended briefly in icecold water and centrifuged again at 20,000 g for 30 min, dissolved instantaneously in 0.3 ml of concentrated HCl, immediately diluted to 5 ml with sufficient NaOH to achieve a pH of 11-12, and analyzed for PPi. A 200-IAd sample was (18) .
Patients. 36 studies were performed in one or both knee joints of 29 volunteers, all patients were from the arthritis clinic or in-patient service at the University of Chicago. 17 studies were done in all patients with definite PG by previously published criteria (20) . 10 patients with chronically symptomatic OA, 5 patients with G proven by specific identification of monosodium urate crystals (21) , and 3 patients with definite RA by the criteria of the American Rheumatism Association (22) were studied. "Acute" or "subacute" is used to designate joints that were tender with detectable increased warmth of the overlying skin and with a synovial fluid leukocyte concentration above 5,000/cm. "Chronic" is used to refer to joints in patients with G or PG that were indistinguishable chemically from symptomatic OA joints. was determined using the roentgenographic criteria of Kellgren and Lawrence (23) . The procedure was explained and informed consent obtained in each instance. Most studies were performed in the out-patient department, but some were performed in the General Clinical Research Center. A summary of clinical data relating to the patients studied is given in Table I . Joint catheterization. The knee joint was catheterized and the end of the catheter connected to a three-way stopcock as described previously (24) .
Nuclide clearance rate. The patient remained supine for the 3-h study period. The (8) . A 50-pl portion of each sample was counted for both 32P and 3P in a solution containing toluene 2,010 ml, PPO 16.5 g, POPOP 0.3 g, and 990 ml Triton X100 per 3 liters of solution. The amount of each isotope present was calculated using the channels ratio method to correct for the mutual spillover of each isotope. The correction factors were determined for each synovial fluid specimen by adding an internal standard of [32P] PPi to a portion of each odd numbered sample and an internal standard of ['-P] Pi to a portion of each even numbered sample. Both the original samples and those containing internal standards were counted for at least 2 cycles. Stability was invariable provided sufficient water was added to bring the total volume to 1 ml.
5 Al of hyaluronidase (1 mg/ml) was added to the 200-/Al heparinized portion of each sample and incubated at room temperature for 10 min. After deproteinization with 6 N HClO4 (final acid normality 0.5), the percentage of [32P]Pi was determined using isobutanol extraction of phosphosmolybdate as described by Hall (18) .
The All samples were brought to the same volume with 0.9% NaCl. After a 3-h incubation, the percent hydrolysis to Pi was determined by isobutanol extraction (18) .
RESULTS
Prcliminary experim~ietts. (a) Rate of exchange of PPi in solution with PPi in CPPD microcrystals: There was no detectable change in specific activity (SA) of PPi in supernatant joint fluid incubated with either natural or synthetic CPPD crystals during incubation periods up to 19 h (Fig. 1) . The decrease in the SA of supernatant PPi exposed to natural CPPD crystals noted between 10 and 30 mmin was probably due to incomiplete mixing of nuclide because the concentration of PPi, as measured chemically, did not change. The SA of PPi in the washed pellets containing synthetic crystals was also constant; only the 17-h pellet of natural crystals contained sufficient PPi for analysis. It contained 0.06 /mol of PPi; unfortunately, the super- (Tables II-V) . Clearance rates could not be calculated in two studies in one patient with neurotrophic joints (patient H. B.) presumably because the severe anatomical disorganization prevented adequate mixing. All patients tolerated the procedure well except one subject with OA (L. J.) who had pain for 48 h after the study. Her synovial fluid remained sterile and it was assumed that the injected solution contained bacterial pyrogen. Infusion of 100 Amol of cold PPi during one study had no influence on the clearance rate of either isotope ( Fig. 2C and D) , suggesting that PPi was leaving the joint by simple diffusion rather than by active transport.
Tuirniozver rate of PPi front the intra-articular pool.
The turnover of PPi per unit time was calculated from the pool size and the turnover rate and is shown in ,.moles per hour for each study in Fig. 3 irrespective of the degree of inflammation present or the clinical diagnosis. All values were separated into three groups according to the extent of radiographically evident degenerative change. The three values from the rheumatoid joints were omitted from this figure because the classification scheme of Lawrence and Kellgren cannot be applied meaningfully. The mean of the group with advanced (grade 4) degeneration was significantly greater than that in the group with mild (grade 0-1) or moderate (grade 2-3) changes (t =3.73 and 3.87; P <0.001), but there was no significant difference between the mild and moderate groups (t = 1.10, 0.2 < P < 0.4). Duplicate studies were possible in four joints. A precision of ±16% was found.
Hydrolysis rates. The rates of hydrolysis varied considerably, being greater in inflamed joints, e.g. G 2-3 4 CHANGE (RADIOLOGIC GRADE) FIGURE 3 The turnover of PPi in the synovial pool, calculated from the pool size and the clearance rate, is plotted for each joint studied according to the degree of degenerative change as estimated radiographically. A, G; U, OA; 0, PG. It should be emphasized that OA changes existed in many joints here labeled as "G" or "PG" on the basis of specific crystal identification. (6, 9) . This is the first comparison of PPi levels in joint fluid with platelet-poor plasma prepared from femoral arterial blood; all previous investigations have used antecubital venous blood for such comparisons. Two of the joint fluids studied here showed joint fluid PPi concentrations that were the same as (study no. 16 in a patient with acute PG) or less than (study no. 35 in a patient with RA) that in the plasma perfusing the joint. The mean turnover rates of the intraarticular PPi pool was greater in RA and clinically inflamed PG joints than it was in OA and chronically symptomatic PG joints, but the values overlapped greatly so that the differences were not as great as one might have predicted from published estimates of joint blood flow in RA and OA joints (27) (28) (29) (Table  II and reference 9 ).
The dissolution rates of synthetic CPPD microcrystals in joint fluid are so slow that it is a matter of several days before apparent saturation is reached. As the intra-articular PPi pool turns over much more rapidly, it is apparent that CPPD crystal dissolution in vivo can contribute little to the PPi concentration of joint fluid. That physical exchange between the PPi in CPPD crystals and PPi in solution could not be detected over a period of 19 h (Fig. 1 ) supports this conclusion. Whether CPPD crystals would appreciably alter joint fluid PPi concentration if incubated over a much longer time is not known.
Preliminary data relative to the apparent solubility of PPi in joint fluid, obtained by incubation of synthetic CPPD labeled with 45Ca, indicates that the joint fluid levels found by ourselves and others are undersaturated with respect to such crystals. If substantiated by further work, the site of nucleation and growth of CPPD crystals is clearly not in synovial fluid despite the frequency of their presence there. Cartilage and similar avascular tissues seem more likely to be the sites of primary formation of mineral phase.
The size of the intra-articular PPi pool and its rate of turnover is not specific for any disease entity. Perhaps, as in the hyperuricemia of G, local elevation of the PPi concentration is a necessary but not sufficient cause of crystal deposition. The analogy with G soon breaks down, as unlike the studies on uric acid pool and turnover, we have no control studies on normal joints. Nor do we really know that the joint space is different with respect to PPi metabolism than any other intercellular space. Deposits of CPPD have been found in the ligamenum muchae (30) and in the dura mater (31) .
We can conclude that the elevated PPi concentration in joint fluid, the intra-articular PPi pool size, and PPi turnover rate are not specific for PG. We can also conclude that the rate of turnover greatly exceeds the rate of crystal dissolution and that the rate of exchange of PPi in solution with that incorporated in microcrystalline CPPD is not measurable over a period of many hours.
